@article{oai:repo.qst.go.jp:00079673,
 author = {Nagai, Yuji and Miyakawa, Naohisa and Takuwa, Hiroyuki and Hori, Yukiko and Oyama, Kei and Ji, Bin and Manami, Takahashi and Xi-Ping, Huang and T. Slocum, Samuel and F. DiBerto, Jeffrey and Xiong, Yan and Urushihata, Takuya and Hirabayashi, Toshiyuki and Fujimoto, Atsushi and Mimura, Koki and G. English, Justin and Liu, Jing and Ken-ichi, Inoue and Kumata, Katsushi and Seki, Chie and Ono, Maiko and Shimojo, Masafumi and Ming-Rong, Zhang and Tomita, Yutaka and Nakahara , Jin and Suhara, Tetsuya and Takada, Masahiko and Higuchi, Makoto and Jin, Jian and L. Roth, Bryan and Minamimoto, Takafumi and Nagai, Yuji and Miyakawa, Naohisa and Takuwa, Hiroyuki and Hori, Yukiko and Oyama, Kei and Ji, Bin and Manami, Takahashi and Urushihata, Takuya and Hirabayashi, Toshiyuki and Fujimoto, Atsushi and Mimura, Koki and Kumata, Katsushi and Seki, Chie and Ono, Maiko and Shimojo, Masafumi and Ming-Rong, Zhang and Tomita, Yutaka and Suhara, Tetsuya and Higuchi, Makoto and Minamimoto, Takafumi},
 issue = {9},
 journal = {Nature Neuroscience},
 month = {Jul},
 note = {The chemogenetic technology Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) affords remotely reversible control of cellular signaling, neuronal activity and behavior. Although the combination of muscarinic-based DREADDs with clozapine-N-oxide (CNO) has been widely used, sluggish kinetics, metabolic liabilities, and potential off-target effects of CNO represent areas for improvement. Here we provide a new high affinity and selective agonist deschloroclozapine (DCZ) for muscarinic-based DREADDs. Positron emission tomography revealed that DCZ selectively bound to and occupied DREADDs in both mice and monkeys. Systemic delivery of low doses of DCZ (1 or 3 μg/kg) enhanced neuronal activity via hM3Dq within minutes in mice and monkeys. Intramuscular injections of DCZ (100 μg/kg) reversibly induced spatial working memory deficits in monkeys expressing hM4Di in the prefrontal cortex. DCZ represents the most potent, selective, metabolically stable and fast-acting DREADD agonist reported with utility in both mice and non-human primates for a variety of applications.},
 pages = {1157--1167},
 title = {Deschloroclozapine, a potent and selective chemogenetic actuator enables rapid neuronal and behavioral modulations in mice and monkeys},
 volume = {23},
 year = {2020}
}